Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GELATO trial of atezolizumab plus carboplatin in metastatic invasive lobular breast cancer
NL-OMON48948Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and carboplatin in breast cancer and Invasive Lobular Carcinoma (ILC), sponsored by Netherlands Cancer Institute. Primary endpoint: 6-month progression-free rate. Started Nov 2017; status: active, not recruiting.
02
Drugs
atezolizumabcarboplatin
03
Conditions
breast cancerInvasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NL-OMON48948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48948.